Sofinnova Investments
CMPX icon

Sofinnova Investments’s Compass Therapeutics CMPX Stock Holding History

Sofinnova Investments’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500,000
Closed -$2.64M – 66
2026
Q1 		$2.64M Buy
+500,000
New +$2.89M 0.1% 60

Other funds holding CMPX

Tang Capital Management
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Suvretta Capital Management
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Enavate Sciences
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Palo Alto Investors
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sofinnova Investments's CMPX Position: Q2 2026 in Review

Sofinnova Investments sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 2,056,161 shares — an estimated $10.9M sold.

Sofinnova Investments first reported a position in CMPX in Q3 2025 and held it in 3 quarters. The position peaked at $18.1M in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Sofinnova Investments reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sofinnova Investments sold 2,056,161 Compass Therapeutics shares in Q2 2026, an estimated $10.9M.
  • Sofinnova Investments first reported a position in Compass Therapeutics in Q3 2025 and held it in 3 quarters.
  • Sofinnova Investments's Compass Therapeutics position peaked at $18.1M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.